Azra AI, the healthcare enterprise platform remodeling most cancers care coordination and medical pathway orchestration by means of superior AI and automation, introduced the appointment of Jessica Turgon to its Board of Administrators.
Turgon is a nationally acknowledged oncology strategist and healthcare govt with many years of expertise advising main well being methods, most cancers facilities, and healthcare organizations on oncology progress, operational transformation, and care supply innovation. She has beforehand labored roles as International Service Line Head for Oncology a Siemens Healthineers and spent 20 years at ECG Administration Consultants, the place she led oncology consulting initiatives for well being methods throughout the nation.
Her appointment comes as well being methods more and more search scalable AI-driven options to enhance most cancers screening, care coordination, operational effectivity, and affected person outcomes amid rising medical and workforce pressures.
“Jessica brings a rare mixture of oncology experience, well being system technique, and operational perception at a pivotal second for healthcare,” stated John Marshall, CEO of Azra AI. “She has spent her profession serving to well being methods navigate complexity and construct stronger oncology applications that enhance affected person care. As Azra continues scaling AI adoption throughout oncology operations, Jessica’s perspective and management will likely be invaluable in serving to us speed up our mission and increase our affect.”
All through her profession, Turgon has suggested healthcare organizations on most cancers service line technique, affected person entry, care supply optimization, doctor alignment, and enterprise transformation initiatives. She is widely known for her deep understanding of the operational and medical challenges going through oncology applications and for serving to organizations modernize care fashions to higher serve sufferers.
At Siemens Healthineers, Turgon lead world oncology technique efforts centered on advancing built-in most cancers care and bettering outcomes by means of innovation and technology-enabled transformation. Throughout her tenure at ECG, she turned recognized for her work serving to hospitals and well being methods strengthen oncology operations whereas sustaining a robust give attention to the affected person expertise.
Additionally Learn: AIThority Interview With Rohit Agarwal, Founder & CEO of Portkey
“Azra AI is addressing one of the vital challenges in healthcare right now: serving to well being methods flip fragmented information into coordinated, actionable care in a single end-to-end platform.” stated Turgon. “The corporate’s means to operationalize AI in a method that immediately helps oncology groups, accelerates affected person identification and therapy, and improves continuity of care is extremely compelling. I’m excited to affix the Board and assist Azra’s continued progress and mission.”
Azra AI’s enterprise platform operationalizes underutilized healthcare information to optimize and orchestrate care and medical trial pathways — guaranteeing sufferers obtain instant, coordinated care inside their well being system, rising affected person retention and outcomes, and making affected person care seen by means of actionable real-time reporting.
By combining superior agentic AI, multimodal information integration, and workflow automation, Azra transforms fragmented medical information into actionable intelligence — powering options throughout lung and breast most cancers screening, incidental findings, multidisciplinary conferences, enterprise affected person administration and care coordination, analysis and medical trial matching, ED discharge workflows, and superior reporting and analytics.
The platform’s means to unify these capabilities inside a single ecosystem allows well being methods to determine sufferers earlier, coordinate care longitudinally, and get rid of gaps throughout the continuum. Deployed throughout a whole bunch of main well being methods, Azra AI helps cut back time to therapy whereas driving measurable enhancements in affected person outcomes, operational effectivity, and ROI at scale.
